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Abstract
Stroke represents a global challenge and is a leading cause of permanent disability worldwide. Despite much effort,
translation of research findings to clinical benefit has not yet been successful. Failure of neuroprotection trials is con-
sidered, in part, due to the low quality of preclinical studies, low level of reproducibility across different laboratories and
that stroke co-morbidities have not been fully considered in experimental models. More rigorous testing of new drug
candidates in different experimental models of stroke and initiation of preclinical cross-laboratory studies have been
suggested as ways to improve translation. However, to our knowledge, no drugs currently in clinical stroke trials have
been investigated in preclinical cross-laboratory studies. The cytokine interleukin 1 is a key mediator of neuronal injury,
and the naturally occurring interleukin 1 receptor antagonist has been reported as beneficial in experimental studies of
stroke. In the present paper, we report on a preclinical cross-laboratory stroke trial designed to investigate the efficacy of
interleukin 1 receptor antagonist in different research laboratories across Europe. Our results strongly support the
therapeutic potential of interleukin 1 receptor antagonist in experimental stroke and provide further evidence that
interleukin 1 receptor antagonist should be evaluated in more extensive clinical stroke trials.
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Introduction
In the UK and Europe, the third leading cause of death
after heart disease and cancers is stroke,1 which causes
greater disability than any other condition.2
Translation of preclinical ﬁndings in stroke to clinical
beneﬁt has not been successful to date and treatment
opportunities are limited to clot lysis and, as demon-
strated recently, thrombectomy.3 However, though
these interventions can provide beneﬁt, they are
restricted to a subset of stroke patients and more
widely applicable treatments are still urgently required,
including ways to minimise brain injury before reperfu-
sion strategies can be implemented. Failure of clinical
stroke trials is thought to be largely due to the
poor quality of preclinical studies, low level of
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reproducibility across research labs and to the fact that
common co-morbidities in stroke (e.g. age, atheroscler-
osis, obesity, etc.) have not been appropriately con-
sidered in preclinical modelling. The Stroke Therapy
Academic Industry Roundtable (STAIR) has estab-
lished detailed recommendations for the evaluation of
preclinical and clinical acute stroke treatments, with
speciﬁc guidelines on improving the quality of experi-
mental studies.4 In addition, initiation of international,
multicentre randomised preclinical trials in transla-
tional stroke research has been suggested,5,6 which
would largely support drug development and selection
of candidates for clinical testing. To our knowledge, no
stroke treatment has yet been tested in a cross-labora-
tory preclinical study.
We have shown that inﬂammatory mechanisms are
central to the pathophysiology of stroke.7,8 In particu-
lar, the cytokine interleukin 1 (IL-1) is a key player in
the pro-inﬂammatory response that underpins the
inﬂammatory component of stroke and other forms
of brain injury.9 Attenuation of inﬂammation after
brain injury by inhibiting endogenous IL-1 is an
attractive therapeutic strategy and use of the naturally
occurring IL-1 receptor antagonist (IL-1Ra) has been
shown as protective in preclinical models of stroke,10
subarachnoid haemorrhage11 and traumatic brain
injury.12 IL-1Ra has also shown promise in a rando-
mised phase II trial in acute ischaemic stroke, which
found it to be safe and well tolerated.13 Despite the
strong evidence in support of IL-1Ra as a treatment
for stroke, there are signiﬁcant translational challenges
in taking successful outcomes from the preclinical to
clinical setting. Methodological quality and diﬀerences
in experimental design between studies and laboratories
can have a profound eﬀect on outcome.14 Therefore, we
initiated a preclinical cross-laboratory study to evaluate
the therapeutic potential of IL-1Ra following middle
cerebral artery occlusion (MCAo) in the mouse.
Materials and methods
Experimental design
Several preclinical stroke research groups across
Europe were approached to participate in a cross-
laboratory study to conﬁrm eﬃcacy of IL-1Ra in
experimental stroke. Invited centres were asked to
respond to the following questions: (1) which species
(e.g. mouse, rat, other?) and strain do/could you use?
(2) Which cerebral ischaemia model(s) are you set up to
do? (3) Which short- and long-term outcome measures
(including behaviour) do/could you use? (4) Could you
do imaging (e.g. serial MRI)? (5) What clinically rele-
vant/co-morbid animal models do/could you use?
Following this initial invitation, four European centres
(Finland, France, Germany, Hungary) were recruited
to join the study in addition to the coordinating
centre in Manchester. On the basis of the responses
obtained regarding capabilities in each of these centres,
a study was then designed to establish the eﬀects of
IL-1Ra in both permanent and transient models of
MCAo with short (24 h), medium (7 d) and longer
term (28 d) assessment of infarct (histology and/or
MRI) and functional outcome. Based on their initial
experiments, a standard operating procedure (SOP)
was drawn up by the Manchester group, and distribu-
ted to all participating centres. However, due to local
practices and availability of resources, the SOP could
not be adhered to and individual research groups con-
ducted the experiments largely according to normal
practice, details of which are described below. All stu-
dies followed the ARRIVE guidelines.15 Summary
details of each study are provided in Table 1.
Induction of ischaemia. All studies used male mice (three
studies with BALB/C and three using C57BL/6) with
four studies using transient models of occlusion (con-
ﬁrmed by blood-ﬂow measurements by laser Doppler)
and four using permanent models (conﬁrmed visually).
The length of occlusion times varied between studies for
transient strokes with three studies giving 30min of
occlusion and another 45min. Studies used animals of
either 2.5 months (six studies) or 10 months (two
studies) of age. Isoﬂurane was used as anaesthetic in
six studies, halothane in one and the injectable tribro-
methanol in another. No analysis was undertaken of
whether the diﬀerent anaesthetics aﬀected outcome as
only one study for each.
Drug treatment. Placebo or IL-1Ra (100mg/kg) was pre-
pared in the lead lab (Manchester) and coded (A or B)
by an independent researcher. Individual tubes labelled
A and B were then sent to the diﬀerent labs taking part
in the study. Animals were randomly assigned either
treatment A or B in the separate studies with blinded
analysis of outcomes in individual studies being com-
pleted by each participating centre. Full datasets were
received from each of these centres by the lead lab
before the allocation code was broken and group iden-
tity revealed. All studies used subcutaneous (s.c.) injec-
tion of IL-1Ra or placebo at 30 and 180min after
MCAo.
Assessment of ischaemic injury. Lesion volumes and
oedema were measured by histological staining (three
studies) or MRI (three studies). All lesion volumes and
oedema measured by staining methods were assessed
seven days post-occlusion while MRI measurements
ranged from 1 to 28 days post-stroke. All lesion and
oedema values were reported in mm3.
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Neurological scoring. Not all centres had equal capacity
with regard to running behavioural assessments and
therefore were provided ﬂexibility to the tests used to
determine neurological deﬁcits post-stroke. Tests used
for functional assessment of outcomes included the
corner (four studies) and catwalk tests (one study).
Detection of sensorimotor asymmetry by the corner
test ranged from 1 to 28 days after MCAo and catwalk
ranged from 3 days prior MCAo (base line) to 28 days
after. Sensorimotor asymmetry (i.e. corner test) was
measured using laterality index, i.e. ipsilateral turns-
contralateral turns/total turns. The higher the score,
the more deﬁcits over a trial period. Neurological def-
icit scoring was recorded in four studies, all lasting up
to seven days (four studies), while two studies went on
longer to 28 days. Recordings of neurological deﬁcit
ranged from 0 to 28 days post-stroke. Two studies
used a modiﬁed neurological deﬁcit scoring system
based on Hunter et al.,16 one study used Bederson
et al.17 and another study assessed behaviour based
on a modiﬁed version of Garcia et al.18 The majority
of neurological scores accumulates points for increasing
deﬁcits. However, the neurological deﬁcit scoring
system based on Hunter is the opposite and more
points are scored for the lack of deﬁcits. In order to
incorporate data from studies using the Hunter scoring
system, Hunter scores were deducted from total max-
imum score (22 points) to produce an inverse value that
can be incorporated into analysis, i.e. Hunter values
showing high scores (lack of deﬁcit) will result in low
values representing a score for neurological deﬁcits
present.
Mortality. Only deaths post-treatment were analysed
and any earlier culling (e.g. due to inadequate occlusion
– as determined by using laser Doppler) does not
amount to attrition bias and therefore is not included
in the meta-analysis. However, all animals that were
culled due to poor condition post-stroke (e.g. they
exhibited barrel-rolling) were included in the analysis.
Details of all deaths, whether included in the meta-ana-
lysis or not were recorded by the coordinating centre
(see section below).
Randomisation/blinding. Animals were randomised to
treatment according to local practice in participating
centres as follows: Budapest – after establishment of
group sizes, GraphPad Random Number Generator
(randomisation for two groups) was used to assign
numbers obtained to individual mice (blocked for
cages, to avoid cage/litter eﬀect); Caen – a random-
isation table was established prior to the study,
and animals were assigned on the day of surgery to
treatment; Kuopio – Graphpad Quikcalcs (http://
www.graphpad.com/quickcalcs/) was used to
randomise animals to treatment; Lubeck – animals
selected at random from cages and assigned either
treatment A or B; Manchester – randomisation
sequence generated in Microsoft Excel, and animals
numbered in advance with selection in order of num-
bering on day of surgery. All assessments were
blinded in accordance with ARRIVE15 and
STAIR19 guidelines.
Exclusion criteria. Data were excluded from the study if
the following were observed: (i) no sustained reduction
(80% of baseline) in cerebral blood ﬂow (CBF)
during occlusion, (ii) lack of reperfusion (where rele-
vant i.e. transient MCAO), (iii) any sign of subarach-
noid haemorrhage/blood vessel rupture, (iv) respiratory
distress/arrest during induction and/or maintenance of
anaesthesia, (v) heart failure during surgery, (vi) seizure
activity (short- or long-term), (vii) severe and pro-
longed weight-loss (typically> 15% over 48 h period).
Exclusion of any data was done prior to unblinding of
the study.
Ethics. Each participating lab conducted all in vivo pro-
cedures in accordance with the European Communities
Council Directive (86/609/EEC) and local/national eth-
ical rules and legislation as follows: Budapest – the
Animal Care and Use Committee of the Institute of
Experimental Medicine, Budapest, Hungary; Caen –
in accordance with French ethical laws (act no. 87–
848; Ministe`re de l’Agriculture et de la Foreˆt) and
approved by the local ethical committee (authorisation
code CENOMEXA 0113-03); Kuopio – the National
Animal Experiment Board in Finland (ELLA) under
license ESAVI-2011-000855; Lubeck – all animal experi-
ments were approved by the local animal welfare com-
mittee (Ministerium fu¨r Energiewende, Landwirtschaft,
Umwelt und la¨ndliche Ra¨ume; Manchester – all proced-
ures were performed under relevant personal and project
licences and adhered to the Animals (Scientiﬁc
Procedures) Act, UK (1986).
Data extraction
Individual data were sought for each animal from each
leading study investigator by a reviewer (RW) unaﬃli-
ated in conducting the studies. All included data were
unpublished. Data retrieved included species, sex, age;
outcomes including functional (e.g. corner test),
neurological scores (e.g. Bederson), oedema (staining
or MRI), lesion volume (MRI or staining); and vital
status (including information on timing and cause of
death – surgery, culling due to poor health, spontan-
eous). Information on treatment was also obtained:
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time of treatment from occlusion time (hours before/
after), loading and maintenance dose of IL-1Ra.
The following study design information was
extracted: experimental model – transient, permanent;
randomisation – randomised, pseudo-randomised, not
randomised; blinding of surgeon to treatment; blinding
of outcome assessors to treatment. Studies were con-
sidered randomised if animals were numbered before
commencement of the study, and a randomisation
code was used to allocate animals to treatment
groups; if animals were ‘picked at random’ from a
cage, then these studies were considered pseudo-rando-
mised since this type of approach is open to bias.
Data analysis
Data were transferred to the project’s coordinating
centre in Manchester by email attachment, e.g. Excel
ﬁle. Study datasets were merged into a single Microsoft
Excel sheet using common ﬁeld names with one row per
animal for analysis. Due to the heterogeneity in study
design, no single outcome measure was assessed in the
same way across the individual experiments. Therefore,
based on the dataset available, it was decided to per-
form a meta-analysis of the individual studies, with
lesion volume, oedema, neurological deﬁcit, functional
outcome and mortality as measures of outcome.
Cochrane Review Manager (version 5.2) was used to
analyse the eﬀect of IL-1Ra treatment compared to
vehicle on post-stroke outcomes. To normalise for dif-
ferences in the absolute lesion volume obtained across
individual centres, individual lesion volumes were rec-
orded as cube root transformations. Oedema values
were reported as either absolute volume or as a percent-
age of the intact contralateral hemisphere. IL-1Ra dose
was standardised to mg/kg. In order to combine the
diﬀerent units, stroke outcomes were standardised by
standard mean diﬀerence (SMD), i.e. the diﬀerence in
means/standard deviation of score, except for lesion
volume for which all values obtained were absolute
and so outcome was reported as mean diﬀerence. An
SMD/mean diﬀerence of zero represents a lack of inter-
vention eﬀect, while a positive or negative value repre-
sents the intervention that favours one treatment
compared to the other. For the corner test, it was
unknown whether the trials in studies were up to a
certain number of turns or timed, hence SMD
was used for analysis. Post-treatment death was com-
pared by odds ratio (OR) analysis. Statistical hetero-
geneity was accounted for through the use of the
DerSimonian and Laird20 pooling model of random
eﬀects in all analysis except for functional test and mor-
tality, where ﬁxed eﬀects were used. Meta-analyses of
IL-1Ra treatment versus vehicle were carried out by
types of outcome, including quantiﬁcation of lesion
volume or oedema by staining method or MRI, neuro-
logical scores, corner test and post-treatment deaths.
Outcome data were stratiﬁed into days of assessment
if outcomes were measured on multiple days.
Publication bias was not assessed in this meta-analysis,
since all available data were obtained from participat-
ing labs.
Data are given as SMD (continuous data), mean dif-
ference (continuous data) or ORs (binary data) with
95% conﬁdence intervals (95% CI), P value for eﬀect,
P value for heterogeneity and P value for interaction; P
values <0.05 are considered signiﬁcant. Negative coeﬃ-
cients imply a reduction in lesion volume. An OR less
than one implies a reduction in death.
Results
Dataset characteristics
The dataset characteristics of the eﬀects of exogenously
administered IL-1Ra versus vehicle on outcomes after
cerebral ischaemia are reported in Table 1. Datasets
were retrieved from eight individual studies conducted
across ﬁve diﬀerent labs and countries (three in the UK
(single lab), one in France, one in Finland, one in
Hungary and one in Germany). Two studies were
split into two datasets each due to diﬀerences in occlu-
sion method (ﬁlament or thrombin) and whether
recombinant tissue plasminogen activator (rtPA) was
added with treatment or not. Data from a total of
241 experimental animals were retrieved.
Lesion volume
The eﬀect of IL-1Ra on lesion size was assessed using
histological staining at seven days (ﬁve studies, seven
datasets) and MRI at diﬀerent times (three studies).
With histological evaluation IL-1Ra reduced lesion
volume, in comparison with vehicle: mean diﬀerence
0.47 (95% conﬁdence interval (CI) 0.68 to 0.27,
P 0.0001) (Figure 1). This corresponds to a mean
reduction in lesion volume of 42.9% (95% CI 24.5–
61.2%), as determined from the eﬀect sizes across indi-
vidual studies. Analysis of MRI determined lesion vol-
umes also found a reduction following IL-1Ra
treatment: mean diﬀerence 0.24 (95% CI 0.37 to
0.11, P¼ 0.0003) (Figure 2). Subgroup analysis of
MRI lesion volumes found IL-1Ra treatment to
reduce lesion size at days 1 (P 0.0001) and 7
(P 0.0001), but not at day 3 (P¼ 0.16) and day 28
post surgery (P¼ 0.59), though these data are derived
from just two studies (one experimenter) at days 1 and
7, and a single study at days 3 and 28 (Figure 2).
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Oedema
Oedema data were retrieved from three studies (four
datasets), which obtained their oedema measurements
via stained sections and two studies using MRI. Data
were available at day 7 for both methods but only at
day 1 for MRI. Histological staining (SMD: 0.31,
95% CI 0.98 to 0.35, P¼ 0.36) (Figure 3) and
MRI measurements (P¼ 0.90) (Figure 4) found no
beneﬁt of IL-1Ra treatment in reducing oedema
volume at day 7. However, oedema measured by
MRI did show IL-1Ra treatment to be beneﬁcial on
day 1 (P¼ 0.04).
Neurological deficit
A total of four studies (ﬁve datasets) were available
for neurological deﬁcit score analysis (Figure 5).
Neurological scores showed IL-1Ra treatment to
reduce neurological at days 1 to 28 (P 0.001) but
not shortly after surgery (P¼ 0.11).
Functional outcome
Corner test data were available from four studies and
overall analysis found IL-1Ra treatment to be beneﬁ-
cial at days 1 (P¼ 0.001), 2 (P 0.001) and 7 (P¼ 0.01)
after stroke but not at day 28 (P¼ 0.34) (Figure 6). Gait
was measured by the catwalk method in a single study
only, so was not analysed in this meta-analysis.
Mortality post treatment
Post-treatment mortality analysis revealed no signiﬁ-
cant diﬀerence between IL-1Ra and vehicle treatment
(OR 1.30, 95% CI 0.50 to 3.42, P¼ 0.59) (Figure 7).
Figure 2. Forest plot of the effect of IL-1Ra on lesion volume measured by MRI.
Figure 1. Forest plot of the effect of IL-1Ra on lesion volume measured by histology.
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Figure 5. Forest plot of the effect of IL-1Ra on neurological deficit.
Figure 4. Forest plot of the effect of IL-1Ra on oedema measured MRI.
Figure 3. Forest plot of the effect of IL-1Ra on oedema measured by histology.
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There were a total of 22 deaths post surgery with 9 other
animals excluded from analysis due to death during sur-
gery (n¼ 5) or exclusion for other reasons (n¼ 4).
Discussion
The objectives of this cross-laboratory study were to
evaluate short-term and long-term eﬀects of IL-1Ra
on stroke outcome after MCAo in rodents, and to
establish the feasibility and challenges faced in running
a multicentre preclinical project. To our knowledge,
this is one of the ﬁrst cross-laboratory preclinical
trials conducted. A meta-analysis of the data was neces-
sary, since no one factor was measured uniformly
across all animals, preventing a grouped analysis as
originally planned. Despite this, the meta-analysis
found IL-1Ra treatment to be beneﬁcial in terms of
reducing lesion damage, neurological deﬁcit and
improving functional outcomes after experimentally
induced stroke in mice.
Figure 6. Forest plot of the effect of IL-1Ra on corner test.
Figure 7. Forest plot of the effect of IL-1Ra on mortality post treatment.
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There has been a great disconnect between preclin-
ical studies and human clinical trials. New therapies or
interventions shown to be eﬀective in animal studies of
stroke have all failed when taken to clinical trial.21
Numerous reasons could explain this but in general
preclinical studies are not always representative of
human clinical trials, particularly with regard to the
lack of multiple site assessment, with single site assess-
ment of eﬃcacy being the norm. Implementing cross-
laboratory studies could therefore bring us one step
closer to successful translation.
The use of diﬀerent models was well represented in
this cross-laboratory study with a mix of both transient
and permanent models. Also, the majority of studies
had data for both functional and lesion volume.
A SOP was provided to participating centres; however,
this was not typically followed, for a variety of reasons,
not least local capabilities and regulations. Diﬀerences
in animal housing surgical protocols and outcome
assessments therefore increased the heterogeneity
within the study. Where possible, we introduced meas-
ures to replicate some of these factors in at least one
additional lab. For example, although the use of
C57BL/6 mice was advised this proved not to be pos-
sible in one site, where BALB/C mice that were mod-
erately aged (10 months) were used instead.
We therefore replicated this study in another site to
allow better comparison of the results.
In clinical trials, the choice of outcome measure can
determine the success or failure of putative therapeutic
intervention.21 In this cross-laboratory study, there was
in the end a lack of deﬁned endpoints and no single
primary outcome that was assessed uniformly in all
participating labs, despite providing an SOP. This was
unexpected and any future multicentre studies should
ensure that participating centres are able to follow
closely the SOP, particularly with respect to outcome
measures, identifying a primary outcome that is
assessed the same in all studies. Harmonisation of pro-
cedures and the provision of SOPs that could be
applied across all centres would also be beneﬁcial.
However, though we were not able to obtain data in
all animals for a single outcome and ended up with a lot
of heterogeneity, this could actually be considered a
strength of the study. There has been much criticism
that preclinical stroke studies lack the heterogeneity
observed in human stroke and that the variation in
our study is actually quite ‘translational’ and strength-
ens the data rather than reduces their reliability. In this
study, the eﬃcacy of IL-1Ra was demonstrated in dif-
ferent strains of mice with diﬀerent occlusion methods
and across several outcome measures.
In terms of lessons learnt from running this study,
centralised collection, preparation and analysis of
brains to determine lesion volume for example would
be advantageous. Similarly, behaviour could be videoed
locally and sent for analysis across several sites to
ensure consistency. The study design should also be
established clearly from the outset, with the total
number of animals for the whole study being deter-
mined through appropriate power analysis.
Participating centres would then receive instructions
as to how many animals to include in the local study.
Randomisation and allocation of treatment should also
be coordinated centrally to ensure consistency and
treatment vials should be individually numbered rather
than just labelled A or B. It should be noted that this
study was conducted very much as proof-of-principle
and with very limited resources, participating labs
kindly agreeing to perform the experiments within their
own budgets. Clearly, any future multicentre preclinical
trial would need to utilise more than one species, intro-
duce aged animals and other co-morbidities, and assess
eﬀects in both male and females. A framework on which
to run multicentre preclinical trials is currently being
developed as part of an EU Framework seven funded
project MultiPART (http://www.dcn.ed.ac.uk/multi
part/), and the lessons learned from this study and
others with cross-laboratory eﬀort are being fed into this.
In conclusion, IL-1Ra treatment was beneﬁcial
overall in this cross-laboratory study in terms of
reducing lesion damage, neurological deﬁcit and
improves functional outcomes after experimentally
induced stroke in a speciﬁc subpopulation of young
to middle-aged male mice. Furthermore, we show
that cross-laboratory preclinical studies are feasible,
but require careful planning and a clearly deﬁned
experimental design.
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